Deutsche Bank AG Raises Holdings in DENTSPLY SIRONA Inc. $XRAY

Key Points

• Deutsche Bank AG increased its stake in DENTSPLY SIRONA Inc. by 292.1% in the first quarter, owning 61,645 shares valued at $921,000.
• DENTSPLY SIRONA recently announced a quarterly dividend of $0.16 per share, equating to an annual yield of 4.4%.
• The company's recent earnings report showed a 4.9% decline in revenue year-over-year, despite exceeding earnings expectations with $0.52 per share.

Deutsche Bank AG grew its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) by 292.1% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 61,645 shares of the medical instruments supplier's stock after buying an additional 45,925 shares during the quarter. Deutsche Bank AG's holdings in DENTSPLY SIRONA were worth $921,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Colonial Trust Co SC acquired a new stake in DENTSPLY SIRONA in the fourth quarter valued at approximately $26,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of DENTSPLY SIRONA in the 1st quarter valued at approximately $25,000. True Wealth Design LLC raised its holdings in shares of DENTSPLY SIRONA by 866.7% in the 4th quarter. True Wealth Design LLC now owns 2,175 shares of the medical instruments supplier's stock valued at $41,000 after purchasing an additional 1,950 shares in the last quarter. Quarry LP lifted its position in shares of DENTSPLY SIRONA by 25.7% during the 4th quarter. Quarry LP now owns 3,816 shares of the medical instruments supplier's stock worth $72,000 after purchasing an additional 780 shares during the last quarter. Finally, Allworth Financial LP grew its stake in shares of DENTSPLY SIRONA by 175.8% during the first quarter. Allworth Financial LP now owns 3,949 shares of the medical instruments supplier's stock worth $54,000 after purchasing an additional 2,517 shares in the last quarter. 95.70% of the stock is owned by institutional investors and hedge funds.

DENTSPLY SIRONA Trading Up 5.5%

NASDAQ:XRAY opened at $14.66 on Monday. The company has a market capitalization of $2.92 billion, a PE ratio of -3.09, a P/E/G ratio of 0.91 and a beta of 0.94. DENTSPLY SIRONA Inc. has a 52-week low of $12.16 and a 52-week high of $27.48. The stock's 50 day moving average price is $15.27 and its 200 day moving average price is $15.47. The company has a quick ratio of 1.11, a current ratio of 1.69 and a debt-to-equity ratio of 1.13.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.02. The business had revenue of $936.00 million during the quarter, compared to the consensus estimate of $929.67 million. DENTSPLY SIRONA had a positive return on equity of 16.33% and a negative net margin of 25.85%.The company's revenue was down 4.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.49 earnings per share. DENTSPLY SIRONA has set its FY 2025 guidance at 1.800-2.000 EPS. On average, research analysts anticipate that DENTSPLY SIRONA Inc. will post 1.84 EPS for the current year.

DENTSPLY SIRONA Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 10th. Investors of record on Friday, September 26th will be paid a dividend of $0.16 per share. The ex-dividend date is Friday, September 26th. This represents a $0.64 dividend on an annualized basis and a yield of 4.4%. DENTSPLY SIRONA's dividend payout ratio is currently -13.50%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Barrington Research cut their price target on DENTSPLY SIRONA from $21.00 to $18.00 and set an "outperform" rating on the stock in a research note on Friday, August 8th. Wall Street Zen lowered DENTSPLY SIRONA from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Wells Fargo & Company decreased their target price on DENTSPLY SIRONA from $16.00 to $15.00 and set an "equal weight" rating for the company in a research note on Friday, August 8th. UBS Group dropped their price target on shares of DENTSPLY SIRONA from $25.00 to $24.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Finally, Piper Sandler cut their price objective on shares of DENTSPLY SIRONA from $20.00 to $16.00 and set a "neutral" rating on the stock in a report on Wednesday, April 30th. Two research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $18.64.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.

Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.